Young Semaglutide Patient Develops Eye Nerve Damage That Reversed After Stopping Drug | Research

The takeaway

A young diabetic patient on semaglutide developed NAION (optic nerve damage) that completely resolved after discontinuing the GLP-1 RA, adding to emerging safety concerns.

Complete resolution
NAION in young semaglutide patient reversed after drug discontinuation

What the researchers found

NAION in a young diabetic patient on semaglutide completely resolved after GLP-1 RA discontinuation, adding to emerging NAION-GLP-1 RA association concerns.

Why it matters

NAION can cause permanent vision loss. If GLP-1 RAs increase NAION risk, millions of users should be aware and monitored, especially those with pre-existing risk factors.

How the study worked

Case report with clinical ophthalmological documentation and follow-up after semaglutide discontinuation.

What this study cannot tell us

Single case report — cannot establish causation; diabetes itself is a NAION risk factor; spontaneous NAION resolution can occur.

How to read the evidence

Case report — lowest evidence level; the complete resolution after drug cessation is suggestive but not proof of causation.

When this study was published

Published 2026 in Cureus.

The bigger picture

Several studies have now flagged a potential NAION-GLP-1 RA association. While individual cases cannot prove causation, the accumulating signal warrants systematic investigation.

Questions still open

Is rapid weight loss from GLP-1 RAs the mechanism for increased NAION risk?
Should ophthalmological screening be recommended for GLP-1 RA users with vision changes?

Common questions

Can semaglutide affect your eyes?

Emerging reports suggest a possible (unproven) association between GLP-1 drugs and a type of optic nerve damage called NAION. This case showed complete recovery after stopping semaglutide, but more research is needed.

What is NAION?

Non-arteritic anterior ischemic optic neuropathy is sudden vision loss caused by reduced blood flow to the optic nerve. Risk factors include diabetes, high blood pressure, and certain eye anatomy features.

Read the original research

Investigating the Link Between Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Non-arteritic Ischemic Optic Neuropathy: A Case Report of Semaglutide-Induced Optic Neuropathy.

Cureus, 18(1), e102472

View on PubMed ↗Publisher’s paper ↗

Citation

Bakheet, Mashair; Chaudhary, Attiqa. (2026). Investigating the Link Between Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Non-arteritic Ischemic Optic Neuropathy: A Case Report of Semaglutide-Induced Optic Neuropathy.. Cureus, 18(1), e102472. https://doi.org/10.7759/cureus.102472